Teva’s experimental anti-PD1-IL2 ATTENUKINE therapy is designed to selectively deliver interleukin-2 to PD-1-expressing T ...

Aravax has announced the appointment of Louise Peacock as its new Chief Regulatory and Quality Officer. Peacock brings over ...

A new investigational treatment has shown strong and lasting responses in multiple myeloma patients with extramedullary ...

iOnctura has announced the appointment Steven Sciuto as its new Chief Financial Officer. Sciuto holds over 15 years of ...

EDX Medical Group has entered into an agreement with Spire Healthcare Group to advance diagnostic innovations aimed at ...

Zusduri, which is delivered directly into the bladder in an out-patient procedure, is now the first and only medication approved by the US regulator to treat adults with recurrent low-grade ...

UCB has announced new three-year data from phase 3 trials and their open-label extensions investigating BIMZELX (bimekizumab) ...

Santen has announced that the European Commission has granted market authorisation for Ryjunea, a low-dose atropine eye drop ...

Argenx has presented positive phase 2 results for efgartigimod in myositis and Sjogren’s disease at EULAR 2025. The company ...

In a move to progress treatment efficacy, oncologists widely agree that, in the future, cancer treatments will become ...

Levicept has presented new data from its phase 2 trial of LEVI-04 at the European Congress of Rheumatology (EULAR 2025). The ...

The PharmaTimes Clinical Researcher of the Year – The Americas 2025 Awards offer an unparalleled opportunity to showcase your ...